1. Home
  2. LVTX

as 10-28-2025 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

LAVA Therapeutics NV isa clinical stage immuno-oncology company. It is focused on transforming cancer treatment by developing a platform to selectively induce bispecific antibody utilizing the Gammabody platform for an undisclosed tumor associated antigen for the treatment of cancer. Company's pipeline include's products such as LAVA-1266, LAVA-1427, LAVA-1433, LAVA-1207, PF08046052, JNJ89853413.

Founded: 2016 Country:
Netherlands
Netherlands
Employees: N/A City: UTRECHT
Market Cap: 40.0M IPO Year: 2021
Target Price: $1.58 AVG Volume (30 days): 513.1K
Analyst Decision: Hold Number of Analysts: 4
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -1.05 EPS Growth: N/A
52 Week Low/High: $0.85 - $2.06 Next Earning Date: 12-09-2025
Revenue: $4,990,000 Revenue Growth: -32.55%
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

LVTX Daily Stock ML Predictions

Stock Insider Trading Activity of LAVA Therapeutics N.V. (LVTX)

Name Ticker Relationship Date Transaction AVG Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Cooperatieve Gilde Healthcare IV U.A. LVTX 10% Owner Oct 17 '25 Sell $1.47 1,181,131 $1,736,262.57 2,947,781
Cooperatieve Gilde Healthcare IV U.A. LVTX 10% Owner Oct 16 '25 Sell $1.49 690,239 $1,028,456.11 2,947,781
Cooperatieve Gilde Healthcare IV U.A. LVTX 10% Owner Oct 14 '25 Sell $1.51 227,341 $343,284.91 2,947,781
Cooperatieve Gilde Healthcare IV U.A. LVTX 10% Owner Oct 13 '25 Sell $1.54 47,686 $73,436.44 2,947,781
Versant Venture Capital VI, L.P. LVTX 10% Owner Sep 19 '25 Sell $1.40 2,903,403 $4,068,828.96 0
Versant Venture Capital VI, L.P. LVTX 10% Owner Sep 18 '25 Sell $1.44 594,902 $857,729.70 0
Versant Venture Capital VI, L.P. LVTX 10% Owner Sep 17 '25 Sell $1.49 589,532 $877,931.05 0
Versant Venture Capital VI, L.P. LVTX 10% Owner Sep 16 '25 Sell $1.53 500,000 $766,600.00 0

Share on Social Networks: